Meningococcal Vaccine Market Size, Share, By Vaccine Type (Conjugative, Polysaccharide, and Others), Serotype (Serotype A, Serotype B, Serotype C, Serotype W, and Serotype Y), Age Group (Infants, Children and Adults), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Healthcare Institutions, and Others) and Region - Trends, Analysis, and Forecast till 2035

Rising Approval for Meningococcal Vaccine for Better Serotype Protection Fuels Market Expansion

New vaccinations are being developed to defend against many serotypes and strains of Neisseria meningitides, while traditional vaccines can only target a small number of meningococcal serogroups. Multiple serotype protection vaccines are being approved by regulatory bodies including the WHO Prequalification Program, the European Medicines Agency (EMA), and the U.S. Food and Drug Administration (FDA) at a quick pace. The market for meningococcal vaccines is expected to develop as a result of the quicker licensing of these vaccinations, which can increase serotype protection, especially in rural regions.